956-09-2

Basic information

• Product Name: 6-benzamidohexanoic acid
• Synonyms: 6-benzamidohexanoic acid;Benzoylaminocaproicacid;6-(Benzoylamino)caproic acid;6-(phenylformamido)hexanoic acid
• CAS NO: 956-09-2
• Molecular Formula: C₁₃H₁₇NO₃
• Molecular Weight: 235.27898
• EINECS: 213-477-7
• Mol File: 956-09-2.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 488.4°Cat760mmHg
• Flash Point: 249.2°C
• Appearance: /
• Density: 1.136g/cm³
• Vapor Pressure: 2.36E-10mmHg at 25°C
• Refractive Index: 1.536
• CAS DataBase Reference: 6-benzamidohexanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-benzamidohexanoic acid(956-09-2)
• EPA Substance Registry System: 6-benzamidohexanoic acid(956-09-2)

Safety Data

• Hazardous Substances Data: 956-09-2(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Tetrahedron Letters, 25, p. 5681, 1984 DOI: 10.1016/S0040-4039(01)91411-X

InChI:InChI=1/C13H17NO3/c15-12(16)9-5-2-6-10-14-13(17)11-7-3-1-4-8-11/h1,3-4,7-8H,2,5-6,9-10H2,(H,14,17)(H,15,16)

Upstream product

• 100-64-1 cyclohexanone-oxime 
• 3653-39-2 N-benzoyl-1H-hexahydroazepine 
• 7732-18-5 water 
• 532-55-8 Benzoyl isothiocyanate 
• 60-32-2 6-aminohexanoic acid 
• 32039-15-9 methyl 6-(4-benzoyl)aminocaproate 
• 105-60-2 caprolactam 
• 121-92-6 3-nitrobenzoic acid 
• 23405-15-4 benzoic acid N-hydroxysuccinimide ester 
• 65-85-0 benzoic acid 
• 147-85-3 L-proline 
• 98-88-4 benzoyl chloride 
• 2453-91-0 N-(4,4-diethoxybutyl)benzamide 
• 137521-24-5 4-(benzoylamino)butanal 

Downstream Products

• 65-85-0 benzoic acid 
• 154978-77-5 2-Benzyloxycarbonyl-1-(benzyloxycarbonylmethyl)ethyl 6-O-[2R-(6-Benzoylaminohexanoylamino)-4-benzyloxycarbonylbutanoyl]-2-deoxy-3-O-tetradecanoyl-2-tetradecanoylamino-α-D-glucopyranoside 
• 1579295-67-2 N-[6-oxo-6-(2-thienyl)hexyl]benzamide 
• 1579295-75-2 N-[(5E)-6-chloro-5-formyl-6-(2-thienyl)hex-5-en-1-yl]benzamide 
• 1579295-71-8 N-[(5Z)-6-chloro-5-formyl-6-(2-thienyl)hex-5-en-1-yl]benzamide 
• 5692-29-5 N-benzoyl-1,5-diaminopentane 
• 5107-18-6 N⁶-benzoyl-lysine 
• 79491-34-2 N-<6-(3,4-dimethoxyphenyl)-6-hydroxyhexyl>benzamide 
• 20308-43-4 N-(1-pentanyl)benzamide 
• 251456-93-6 N-benzyloxy-6-(4-benzoyl)aminocapramide 
• 1700-05-6 6-benzamido-2-bromohexanoic acid 

Relevant articles and documents

Catalytic synthesis of N-benzoyl (N-nitrobenzoyl) derivatives of ε-aminocaproic acid oligomers

The synthesis of N-benzoyl [N-(m-nitrobenzoyl)] derivatives of ε-aminocaproic acid oligomers by the reaction of ε-caprolactam with benzoic (nitrobenzoic) acid in the presence of p-toluenesulfonic acid as catalyst was studied. Pleiades Publishing, Inc., 2006.

Preparation method and application of benzamide derivative

The invention discloses a preparation method and application of a benzamide derivative as shown in a formula (I) which is described in the specification. The objective of the invention is to improve the chelation stability of zinc ions of histone deacetylase in the prior art so as to obtain HDACi with better histone deacetylase inhibition effect and stronger selectivity. The derivative provided bythe invention can be applied to preparation of antitumor drugs and is capable of improving the capability of HDACi in selection of a part of tumor cells and substantially reducing cytotoxicity.

Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR

Enzymatic inhibition of histone deacetylase (HDAC) activity is emerging as an innovative and effective approach for the treatment of cancer. A series of novel amide derivatives have been synthesized and evaluated for their ability to inhibit human HDACs. Multiple compounds were identified as potent HDAC inhibitors (HDACi), with IC50 values in the low nanomolar (nM) range against enzyme activity in HeLa cell extracts and sub-μM for their in vitro anti-proliferative effect on cell lines. The introduction of an unsaturated linking group between the terminal aryl ring and the amide moiety was the key to obtain good potency. This approach yielded compounds such as (E)-N-[6-(hydroxyamino)-6-oxohexyl]-3-(7-quinolinyl)-2-propenamide (27) (HDAC IC50 8 nM) which showed potent in vivo activity in the P388 mouse leukemia syngeneic model (an increased lifespan (ILS) of 111% was obtained).